



Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China

Anding Liu, MD; Ying Li, MS; Zhengce Wan, MS; Wenjie Wang, MS; Xiaomei Lei, MD; Yongman Lv, MD

Introduction

A large number of individuals with coronavirus disease 2019 (COVID-19) infections might present with no or only mild symptoms, and the reported numbers of patients with COVID-19 do not reflect the true scale of the outbreak.^{1,2} Therefore, population-based serological studies are urgently needed to understand the epidemiological characteristics of the outbreak and the population's immunity to COVID-19.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Methods

This cross-sectional study was conducted in Tongji Hospital of Huazhong University of Science and Technology between March 27 and May 26, 2020. This study was approved by the ethics committee of Tongji Hospital of Huazhong University of Science and Technology. Informed consent was waived because deidentified data were used. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.


Adult participants aged 18 years or older were enrolled in the current study. None of the participants had a history of COVID-19. Demographic data, including age, sex, and residential region, were collected. The participants were screened for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by serological tests for IgM and IgG antibodies to SARS-CoV-2³ and by real-time reverse transcriptase–polymerase chain reaction tests for SARS-CoV-2 RNA.⁴ Additional details

Table. SARS-CoV-2 Seropositive Prevalence in Different Age Groups

Age group, y	Patients, No.	Male, %	SARS-CoV-2 seropositive prevalence, patients, No. (%) [95% CI]
18-29	8163	44.5	232 (2.8) [2.5-3.2]
30-39	13 471	44.3	524 (3.9) [3.6-4.2]
40-49	7713	52.3	313 (4.1) [3.6-4.5]
50-59	4932	64.7	221(4.5) [3.9-5.1]
≥60	761	49.3	70 (9.2) [7.1-11.3]

Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure. Severe Acute Respiratory Syndrome Coronavirus 2 Seropositive Prevalence by Sex and Age Group



Open Access. This is an open access article distributed under the terms of the CC-BY License.

about the methods, including information on the statistical analysis, are provided in the eAppendix in the [Supplement](#).

Results

A total of 35 040 individuals (17 269 men [49.3%] and 17 771 women [50.7%]) were enrolled in this study. The median (interquartile range) age was 36 (30-45) years. The positivity rate for IgM antibodies only was 0.0%, that for both IgM and IgG antibodies was 0.7%, and that for IgG antibodies only was 3.2%. Most individuals (1100 of 1360 individuals [80.9%]) tested positive for IgG antibodies only. The overall seropositivity rate was 3.9% (95% CI, 3.7%-4.1%). We observed that very few individuals (15 of 35 040 individuals [0.04%]) had detectable SARS-CoV-2 viral nucleic acid sequence and tested negative during their quarantine period, and none of their close contacts had positive nucleic acid test results. The seropositive prevalence in the urban districts was higher than that in the suburban and rural areas (4.4% [95% CI, 4.0%-4.8%] vs 2.9% [95% CI 2.3%-3.6%]; $P < .001$), demonstrating an urban to suburban gradient. Moreover, women had higher seropositive prevalence than did men (4.4% [95% CI, 4.1%-4.6%] vs 3.3% [95% CI, 3.1%-3.6%]; $P < .001$). We did observe that seropositive prevalence was associated with increasing age, with the highest rates among individuals aged 60 years and older (9.2% [95% CI, 7.1%-11.3%]; $P < .001$) (**Table** and **Figure**).

Discussion

This study found that the seropositive prevalence was 3.9% in a cohort of 35 040 individuals in Wuhan, China. Most individuals tested positive for SARS-CoV-2 IgG antibodies only, indicating a prior infection. We further showed that the seropositive prevalence in the urban districts was higher than that in the suburban and rural areas, which is consistent with the geographical distribution of confirmed cases, with the highest rates in the urban districts.⁵ Moreover, women had a higher seropositive prevalence than did men, which is consistent with a previous report⁵ showing that female individuals had higher rates of confirmed cases compared with male individuals. The seropositive prevalence was also significantly higher among elderly individuals than in other age groups. It is possible that elderly people had a higher proportion of comorbid conditions, which might facilitate SARS-CoV-2 infection and increase the severity of COVID-19.⁵

Our study has several limitations. Although the overall sample size was large, there were few participants older than 60 years and none of the participants were younger than 18 years, which limited our ability to estimate seropositive prevalence among elderly people and children. Because most of the participants came from urban districts with higher infection rates, seropositive prevalence may not be accurate. Because the specific antibodies against SARS-CoV-2 might wane over time in some convalescent COVID-19 individuals,⁶ asymptomatic cases who had low levels of antibodies might be more likely to become negative in population-based studies.

ARTICLE INFORMATION

Accepted for Publication: September 8, 2020.

Published: October 23, 2020. doi:10.1001/jamanetworkopen.2020.25717

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2020 Liu A et al. *JAMA Network Open*.

Corresponding Author: Yongman Lv, MD, Health Management Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430030, Hubei, China (lvongman@126.com).

Author Affiliations: Experimental Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (Liu, Li); Health Management Center, Tongji Hospital, Tongji Medical

College, Huazhong University of Science and Technology, Wuhan, China (Wan, Wang, Lei, Lv).

Author Contributions: Dr Lv had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Liu, Lei, Lv.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Liu, Lei, Lv.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Liu, Li, Wan.

Obtained funding: Liu.

Administrative, technical, or material support: All authors.

Supervision: Lv.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported by grant 91849127 from the National Natural Science Fund of China.

Role of the Funder/Sponsor: The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

1. Wang Y, Kang H, Liu X, Tong Z. Asymptomatic cases with SARS-CoV-2 infection. *J Med Virol*. Published online May 8, 2020. doi:10.1002/jmv.25990
2. Qiu J. Covert coronavirus infections could be seeding new outbreaks. *Nature*. Published online March 20, 2020. doi:10.1038/d41586-020-00822-x
3. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*. 2020; 26(6):845-848. doi:10.1038/s41591-020-0897-1
4. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. *Clin Infect Dis*. Published online April 17, 2020. doi:10.1093/cid/ciaa449
5. Pan A, Liu L, Wang C, et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. *JAMA*. 2020;323(19):1915-1923. doi:10.1001/jama.2020.6130
6. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6

SUPPLEMENT.

eAppendix. Supplemental Methods

eReferences